‘Why Biology Is Not Destiny’: An Exchange
By Kathryn Paige Harden et al.,
The New York Review
| 05. 25. 2022
Kathryn Paige Harden, Nick Patterson, Victor I. Reus, and Henry D. Schlinger Jr., reply by M.W. Feldman and Jessica Riskin
In response to:
Why Biology Is Not Destiny from the April 21, 2022 issue
To the Editors:
Marcus Feldman and Jessica Riskin did not like my book. Or rather, they did not like a book called The Genetic Lottery by an author named “Kathryn Paige Harden,” but their review [NYR, April 21] so badly distorts my arguments that I have the curious impression that Feldman and Riskin somehow got their hands on another book entirely, an evil doppelgänger to mine. Therapists, parents, and the unhappily married would recognize the feeling I had upon reading their review the first time: it’s both vexing and bewildering when someone is spoiling for a fight about something you never said.
As a longtime reader of The New York Review of Books, I am surprised and disappointed that this review was published in such an esteemed outlet. Yes, “we all enjoy an intemperate paragraph of syntactically inspired bile,” to quote Zadie Smith, and Feldman and Riskin do deliver the bile. But I assume that, besides wanting to be entertained by vitriol...
Related Articles
By Aisha Down, The Guardian | 11.10.2025
It has been an excellent year for neurotech, if you ignore the people funding it. In August, a tiny brain implant successfully decoded the inner speech of paralysis patients. In October, an eye implant restored sight to patients who had...
By Jessica Hamzelou, MIT Technology Review | 11.07.2025
This week, we heard that Tom Brady had his dog cloned. The former quarterback revealed that his Junie is actually a clone of Lua, a pit bull mix that died in 2023.
Brady’s announcement follows those of celebrities like Paris...
By Heidi Ledford, Nature | 10.31.2025
Late last year, dozens of researchers spanning thousands of miles banded together in a race to save one baby boy’s life. The result was a world first: a cutting-edge gene-editing therapy fashioned for a single person, and produced in...
By Lauran Neergaard, AP News | 11.03.2025
WASHINGTON (AP) — The first clinical trial is getting underway to see if transplanting pig kidneys into people might really save lives.
United Therapeutics, a producer of gene-edited pig kidneys, announced Monday that the study’s initial transplant was performed successfully...